Emergent BioSolutions | EBS - Операционный доход





Операционный доход Изменить Дата
Acadia Pharmaceuticals USD 17.39M 18.36M 2025-12
Akebia Therapeutics USD 13.51M 27.82M 2025-03
ALKERMES USD -10.95M 100.03M 2025-12
Alnylam Pharmaceuticals USD 29.4M 59.36M 2025-12
Amarin USD -1.7M 8.47M 2025-09
ANI Pharmaceuticals USD 29.13M 6.3M 2025-12
BioMarin Pharmaceutical USD 198.39M 230.08M 2025-12
Coherus Biosciences USD -45.43M 3.13M 2025-03
Emergent BioSolutions USD -218M 69.9M 2023-06
Exact Sciences USD -25M 22.85M 2025-09
Exelixis USD 235.91M 20.45M 2025-12
Glaxosmithkline GBP 3.76B 1.32B 2025-09
Heron Therapeutics USD -5.66M 782K 2024-09
Ionis Pharmaceuticals USD -215M 54.82M 2025-12
Ironwood Pharmaceuticals USD 33.22M 7.58M 2024-12
Lexicon Pharmaceuticals USD -55.35M 10.02M 2024-06
Lonza CHF 430M 104M 2024-12
Merck USD 6.24B 318M 2025-12
Moderna USD -857M 597M 2025-12
Myriad Genetics USD -23.3M 10.8M 2025-09
Nektar Therapeutics USD -34.34M 15.43M 2024-09
Neurocrine Biosciences USD 227.9M 11.4M 2025-12
Pacira USD 3.19M 9.96M 2025-12
Pfizer USD 4.65B 3.99B 2025-12
PTC Therapeutics USD -81.62M 85.11M 2025-12
Sanofi EUR 1.7B 2.17B 2025-12
Sarepta Therapeutics USD -410.08M 347.2M 2025-12
United Therapeutics USD -14.6M 403.9M 2025-12
Vanda Pharmaceuticals USD -40.66M 29.66M 2024-12
Xoma USD -15.64M 5.56M 2024-09